Compounds > 1-anilino-8-naphthalenesulfonate
Page last updated: 2024-10-21

1-anilino-8-naphthalenesulfonate and Wet Macular Degeneration

1-anilino-8-naphthalenesulfonate has been researched along with Wet Macular Degeneration in 3 studies

1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd
8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.

Wet Macular Degeneration: A form of RETINAL DEGENERATION in which abnormal CHOROIDAL NEOVASCULARIZATION occurs under the RETINA and MACULA LUTEA, causing bleeding and leaking of fluid. This leads to bulging and or lifting of the macula and the distortion or destruction of central vision.

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Fernández-Vega, B1
García, M1
Olivares, L1
Álvarez, L1
González-Fernández, A1
Artime, E1
Fernández-Vega Cueto, A1
Cobo, T1
Coca-Prados, M1
Vega, JA1
González-Iglesias, H1
Lin, LY1
Zhou, Q1
Hagstrom, S1
Maguire, MG2
Daniel, E2
Grunwald, JE1
Martin, DF2
Ying, GS2
Jaffe, GJ1
Toth, CA1
Grunwald, J1
Hagstrom, SA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)[NCT00593450]Phase 31,208 participants (Actual)Interventional2008-02-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Area of Lesion

(NCT00593450)
Timeframe: at 1 Year

Interventionmm^2 (Mean)
1-Lucentis Monthly6.6
2-Avastin Monthly6.5
3-Lucentis as Needed7.3
4-Avastin as Needed7.0

Area of Lesion Change From Baseline

(NCT00593450)
Timeframe: Baseline and 1 Year

Interventionmm^2 (Mean)
1-Lucentis Monthly-0.1
2-Avastin Monthly0.3
3-Lucentis as Needed0.6
4-Avastin as Needed1.3

Average Cost of Drug/Patient

(NCT00593450)
Timeframe: at 1 Year

InterventionUS dollars per patient (Mean)
1-Lucentis Monthly23400
2-Avastin Monthly595
3-Lucentis as Needed13800
4-Avastin as Needed385

Change From Baseline in Visual-acuity Score (Continuous)

"Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly. The VA score change is the difference of the VA score at 1 Year and the VA score at baseline.~In this study, the outcome VA score change is ranged from -71 to 52, with the higher VA score change the better visual acuity improvement." (NCT00593450)
Timeframe: Baseline and 1 Year

InterventionNo. of Letters (Mean)
1-Lucentis Monthly8.5
2-Avastin Monthly8.0
3-Lucentis as Needed6.8
4-Avastin as Needed5.9

Change in Diastolic Blood Pressure From Baseline

(NCT00593450)
Timeframe: Baseline and 1 Year

Interventionmm Hg (Mean)
1-Lucentis Monthly-0.9
2-Avastin Monthly-1.4
3-Lucentis as Needed-1.9
4-Avastin as Needed-2.1

Change in Systolic Blood Pressure From Baseline

(NCT00593450)
Timeframe: Baseline and 1 Year

Interventionmm Hg (Mean)
1-Lucentis Monthly-2.1
2-Avastin Monthly-5.4
3-Lucentis as Needed-5.2
4-Avastin as Needed-4.5

Number of Treatments

Cumulative over the 1 year of trial (NCT00593450)
Timeframe: 1 Year

InterventionNumber of Treatments (Mean)
1-Lucentis Monthly11.7
2-Avastin Monthly11.9
3-Lucentis as Needed6.9
4-Avastin as Needed7.7

Retinal Thickness Plus Subfoveal-fluid Thickness at Fovea

(NCT00593450)
Timeframe: at 1 Year

Interventionμm (Mean)
1-Lucentis Monthly152
2-Avastin Monthly172
3-Lucentis as Needed166
4-Avastin as Needed172

Retinal Thickness Plus Subfoveal-fluid Thickness Change From Baseline at Fovea

(NCT00593450)
Timeframe: Baseline and 1 Year

Interventionμm (Mean)
1-Lucentis Monthly-100
2-Avastin Monthly-79
3-Lucentis as Needed-81
4-Avastin as Needed-79

Total Thickness at Fovea

(NCT00593450)
Timeframe: at 1 Year

Interventionμm (Mean)
1-Lucentis Monthly266
2-Avastin Monthly300
3-Lucentis as Needed294
4-Avastin as Needed308

Total Thickness Change From Baseline at Fovea

(NCT00593450)
Timeframe: Baseline and 1 Year

Interventionμm (Mean)
1-Lucentis Monthly-196
2-Avastin Monthly-164
3-Lucentis as Needed-168
4-Avastin as Needed-152

Visual-acuity Score and Snellen Equivalent (Continuous)

"Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly.~In this study, the outcome VA score is ranged from 0 to 97, with the higher score the better visual acuity." (NCT00593450)
Timeframe: at 1 Year

InterventionNo. of Letters (Mean)
1-Lucentis Monthly68.8
2-Avastin Monthly68.4
3-Lucentis as Needed68.4
4-Avastin as Needed66.5

Change From Baseline Visual-acuity Score (Frequency)

(NCT00593450)
Timeframe: Baseline and 1 Year

,,,
InterventionParticipants (Number)
Increase of ≥15 lettersIncrease of 5-14 lettersChange of ≤4 lettersDecrease of 5-14 lettersDecrease of ≥15 letters
1-Lucentis Monthly9790621916
2-Avastin Monthly8398501816
3-Lucentis as Needed71103752313
4-Avastin as Needed7690592323

Dye Leakage on Angiogram

(NCT00593450)
Timeframe: at 1 Year

,,,
InterventionParticipants (Number)
AbsentPresentData missing
1-Lucentis Monthly1679720
2-Avastin Monthly15310012
3-Lucentis as Needed13313715
4-Avastin as Needed11114515

Fluid on Optical Coherence Tomography

(NCT00593450)
Timeframe: at 1 Year

,,,
InterventionParticipants (Number)
AbsentPresentData missing
1-Lucentis Monthly1241519
2-Avastin Monthly691888
3-Lucentis as Needed6820314
4-Avastin as Needed522145

Visual-acuity Score and Snellen Equivalent (Frequency)

(NCT00593450)
Timeframe: at 1 Year

,,,
InterventionParticipants (Number)
83-97 letters, 20/12-2068-82 letters, 20/25-4053-67 letters, 20/50-8038-52 letters, 20/100-160≤37 letters, ≤20/200
1-Lucentis Monthly42149522318
2-Avastin Monthly45134472118
3-Lucentis as Needed38141662317
4-Avastin as Needed40127572423

Trials

1 trial available for 1-anilino-8-naphthalenesulfonate and Wet Macular Degeneration

ArticleYear
Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    JAMA ophthalmology, 2016, Jun-01, Volume: 134, Issue:6

    Topics: Aged; Aged, 80 and over; Complement C2; Complement C3; Complement Factor B; Complement Factor H; Cro

2016

Other Studies

2 other studies available for 1-anilino-8-naphthalenesulfonate and Wet Macular Degeneration

ArticleYear
The association study of lipid metabolism gene polymorphisms with AMD identifies a protective role for APOE-E2 allele in the wet form in a Northern Spanish population.
    Acta ophthalmologica, 2020, Volume: 98, Issue:3

    Topics: Aged; Aged, 80 and over; Alleles; Apolipoprotein E2; Case-Control Studies; Female; Genotype; Humans;

2020
Association of Single-Nucleotide Polymorphisms in Age-Related Macular Degeneration With Pseudodrusen: Secondary Analysis of Data From the Comparison of AMD Treatments Trials.
    JAMA ophthalmology, 2018, 06-01, Volume: 136, Issue:6

    Topics: Aged; Angiogenesis Inhibitors; Complement C2; Complement C3; Complement Factor B; Complement Factor

2018